Harpoon therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Harpoon therapeutics Contact Number

Contact Harpoon Therapeutics

4 hours ago Harpoontx.com Show details

(650) 443-7400Contact information for Harpoon Therapeutics, an immuno-oncology company using a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. Contact. Harpoon Therapeutics. 131 Oyster Point Blvd, Suite 300

1. 131 Oyster Point Blvd Ste 300, South San Francisco, CA 94080

Category: Contact SupportShow more

Harpoon Therapeutics, Inc. Company Profile South San

8 hours ago Dnb.com Show details

(650) 443-7400Address. 131 Oyster Point Blvd Ste 300. South San Francisco , CA , 94080-2032. United States. Phone. (650) 443-7400. Company Description. Harpoon Therapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Biotechnology Research Services Industry. Harpoon Therapeutics, Inc. has 45 total employees across all of its

Employees: 45
Phone: (650) 443-7400
Location: 131 Oyster Point Blvd Ste 300, South San Francisco, 94080-2032, CA

Category: Contact NumberShow more

Harpoon Therapeutics Crunchbase Company Profile & …

Just Now Crunchbase.com Show details

650-443-7400Contact Email [email protected] Phone Number 650-443-7400. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s

Founder: Luke Evnin, Patrick Baeuerle
Location: South San Francisco, California
Founded: Jan 01, 2015

Category: Contact NumberShow more

Harpoon therapeutics Email Addres & Phone Number Lusha

8 hours ago Lusha.com Show details

Lusha Extension Find contact data on the web; Prospecting Platform Build accurate Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Number of employees. 51 - 200. Main

Employees: 51-200

Category: Phone NumberShow more

Harpoon Therapeutics Immunooncology TriTAC™

6 hours ago Harpoontx.com Show details

December 13, 2021. Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms. December 11, 2021. Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and …

Category: Contact NumberShow more

Harpoon Therapeutics to Host Pipeline Update Call and

5 hours ago Finance.yahoo.com Show details

650-443-7400Contacts: Harpoon Therapeutics, Inc. Georgia Erbez Chief Financial Officer 650-443-7400 [email protected] Westwicke ICR Robert H. Uhl Managing Director

Category: Contact NumberShow more

Harpoon Therapeutics Harpoon Therapeutics, Inc.

4 hours ago Ir.harpoontx.com Show details

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific

Category: Contact NumberShow more

Harpoon Trademark Harpoon Therapeutics, Inc. South San

8 hours ago Bizapedia.com Show details

Mark Identification: HARPOON: Last Applicant/Owner: Harpoon Therapeutics, Inc. 4000 Shoreline Court, Suite 250 South San Francisco, CA 94080 : Serial Number:

Category: Contact NumberShow more

HARP Harpoon Therapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

These and other factors that may cause Harpoon Therapeutics' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics' filings with the U.S. Securities and Exchange Commission, including under "Risk Factors" in Harpoon Therapeutics' quarterly report on

Category: Contact NumberShow more

Frank Lanza Controller Harpoon Therapeutics …

9 hours ago Zoominfo.com Show details

View Frank Lanza's business profile as Controller at Harpoon Therapeutics. Find contact's direct phone number, email address, work history, and more.

Category: Contact NumberShow more

Study of HPN536 in Patients With Advanced Cancers

7 hours ago Clinicaltrials.gov Show details

844-482-4812Contact: Sarah Cannon Research Institute : Contact 1-844-482-4812 : United States, Texas: Mary Crowley Cancer Research: Recruiting: Dallas, Texas, United States, 75230 : Contact: Mary Crowley Cancer Research 972-566-3000 [email protected] : United States, Virginia: University of Virginia Cancer Center: Recruiting

Category: Contact NumberShow more

Harpoon Therapeutics Funding, Financials, Valuation

9 hours ago Crunchbase.com Show details

Harpoon Therapeutics has raised a total of $130M in funding over 3 rounds. Their latest funding was raised on Nov 12, 2018 from a Series C round. Harpoon Therapeutics is registered under the ticker NASDAQ:HARP . Their stock opened with $14.00 in its Feb 7, 2019 IPO. Harpoon Therapeutics is funded by 10 investors.

Category: Contact NumberShow more

Harpoon Therapeutics Granted Orphan Drug Designation from

3 hours ago Ir.harpoontx.com Show details

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of …

Category: Contact NumberShow more

Current Report Filing (8k)

2 hours ago Ih.advfn.com Show details

HARP Harpoon Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Category: Contact NumberShow more

Chancery Finds Fraud In Cancer Drug Firm's Spinoff Deal

5 hours ago Law360.com Show details

The case is Maverick Therapeutics Inc. and Millennium Pharmaceuticals Inc. v. Harpoon Therapeutics Inc., case number 2019-0002, in the Court of Chancery of the State of Delaware. --Editing by Jack

Category: Contact NumberShow more

Harpoon Therapeutics, Inc. (HARP) Stock Price, Quote

8 hours ago Stockanalysis.com Show details

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the 2 months ago - Zacks Investment Research.

Category: Contact NumberShow more

Study of HPN424 in Patients With Advanced Prostate Cancer

7 hours ago Clinicaltrials.gov Show details

Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added. In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion. In Part 2 (Dose Expansion), HPN424 will be administered at the recommended phase 2 dose (s) once weekly

Category: Contact NumberShow more

Harpoon Therapeutics : Presents Interim Clinical Data from

Just Now Marketscreener.com Show details

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC ® HPN217 at the 63 rd ASH Annual Meeting and Exposition. Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with …

Category: Contact NumberShow more

Harpoon initiates HPN536 Phase 1/2a clinical trial Arix

2 hours ago Arixbioscience.com Show details

SOUTH SAN FRANCISCO, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that the first patient has been dosed with HPN536 in a Phase 1/2a clinical trial initially focused on ovarian cancer.

Category: Contact NumberShow more

DEF 14A SEC

5 hours ago Sec.gov Show details

Harpoon Therapeutics, Inc. Aggregate number of securities to which transaction applies: (3) If your shares are held in street name, please contact the telephone number provided on your voting instruction form or contact your broker or nominee holder directly. 7 .

Category: Contact NumberShow more

Harpoon Therapeutics Number of Employees 20172021 HARP

7 hours ago Macrotrends.net Show details

Harpoon Therapeutics number of employees from 2017 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which

Category: Contact NumberShow more

Harpoon Therapeutics Company Profile Office Locations

7 hours ago Craft.co Show details

Harpoon Therapeutics has 45 employees across 3 locations and $17.44 M in annual revenue in FY 2020. See insights on Harpoon Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Category: Contact NumberShow more

Harpoon Arix Bioscience

4 hours ago Arixbioscience.com Show details

Harpoon announces proposed public offering in the United States. Arix. 25th May 2017. Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics. Our Portfolio. Keep browsing through the other companies in our portfolio.

Category: Contact NumberShow more

Harpoon Therapeutics, Inc. (HARP) 10K Annual Reports & 10Q

6 hours ago Last10k.com Show details

Harpoon Therapeutics, Inc. Portions of the definitive proxy statement, or the Proxy Statement, for the 2021 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the

Category: Contact NumberShow more

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus

1 hours ago Marketbeat.com Show details

Harpoon Therapeutics has a one year low of $5.53 and a one year high of $25.24. Harpoon Therapeutics (NASDAQ:HARP) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01.

Category: Contact NumberShow more

Should Biotechnology Stock Harpoon Therapeutics Inc (HARP

7 hours ago Investorsobserver.com Show details

Harpoon Therapeutics Inc is near the middle in its industry group according to InvestorsObserver.HARP gets an overall rating of 36. That means it scores higher than 36 percent of stocks. Harpoon Therapeutics Inc gets a 47 rank in the Biotechnology industry. Biotechnology is number 103 out of 148 industries.

Category: Tech SupportShow more

Harpoon Therapeutics hiring Senior/Principal Statistical

9 hours ago Linkedin.com Show details

Posted 4:39:32 PM. Harpoon Therapeutics is a clinical-stage immunotherapy company located in South San Francisco. The…See this and similar jobs on LinkedIn.

Category: Contact NumberShow more

HARP Stock Price Harpoon Therapeutics Inc. Stock Quote

8 hours ago Marketwatch.com Show details

Harpoon Therapeutics started at buy with $31 stock price target at SunTrust RH Feb. 28, 2020 at 8:09 a.m. ET by Tomi Kilgore Harpoon Therapeutics started at outperform with $23 stock price target

Category: Contact NumberShow more

Ansbert Gadicke Net Worth, Biography & Insider Trading History

7 hours ago Insidertrades.com Show details

The corporate mailing address for Dr. Gadicke and other Harpoon Therapeutics executives is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Harpoon Therapeutics can also be reached via phone at …

Category: Contact NumberShow more

Sierra Oncology Targeted Cancer Treatments About Us

7 hours ago Sierraoncology.com Show details

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease, advancing therapies on the leading edge of …

Category: Contact NumberShow more

How to buy Harpoon Therapeutics stock 30 Dec price $7.55

6 hours ago Finder.com Show details

Harpoon Therapeutics share price volatility. Over the last 12 months, Harpoon Therapeutics's shares have ranged in value from as little as $5.53 up to $25.235. A popular way to gauge a stock's volatility is its "beta". HARP.US volatility (beta: 0.72) Avg. volatility (beta: 1.00) Low High. Beta is a measure of a share's volatility in relation to

Category: Contact NumberShow more

Harpoon Therapeutics : Corporate Presentation – January

4 hours ago Marketscreener.com Show details

Harpoon Therapeutics : Corporate Presentation – January 2022. This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "target," "estimate" and similar expressions (as well as

Category: Contact NumberShow more

Protritac Trademark Harpoon Therapeutics, Inc. South

Just Now Bizapedia.com Show details

Protritac is a Trademark by Harpoon Therapeutics, Inc., this trademark has a nationality of Delaware in the United States. PROTRITAC: Last Applicant/Owner: Harpoon Therapeutics, Inc. Delaware · United States: Serial Number: 88168272: Filing Date: October 24, 2018: Status: Fourth Extension - Granted: Status Date: August 10, 2021

Category: Contact NumberShow more

Cherry Biolabs GmbH VentureRadar

2 hours ago Ventureradar.com Show details

Harpoon Therapeutics USA Private Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, PhD, a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases.

Category: Contact NumberShow more

2021 Report: Worldwide Trispecific Antibody Market

8 hours ago Finance.yahoo.com Show details

DUBLIN, Nov. 22, 2021 /PRNewswire/ -- The "Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The advent of

Category: Contact NumberShow more

Scrip

9 hours ago Scrip.pharmaintelligence.informa.com Show details

(212) 520-2765Please contact Sales at: (212) 520-2765 or email [email protected] Latest From Harpoon Therapeutics Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs

Category: Contact NumberShow more

Maverick Therapeutics, Inc. v. Harpoon Therapeutics, Inc

3 hours ago Law.com Show details

After finding that defendant Harpoon Therapeutics, Inc. had committed fraud in the sale of its spin-off, plaintiff Maverick Therapeutics, Inc., the court issued its decision on damages. Harpoon

Category: Contact NumberShow more

Harpoon Therapeutics hiring Research Associate, New

3 hours ago Linkedin.com Show details

Posted 4:32:08 PM. Harpoon Therapeutics is a clinical-stage immuno-oncology company focused on the discovery and…See this and similar jobs on LinkedIn.

Category: Contact NumberShow more

Outlook on the Trispecific Antibody Global Market to 2028

3 hours ago Benzinga.com Show details

917-300-0470CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office

Category: Contact NumberShow more

Pyxis Oncology Contact Us

4 hours ago Pyxisoncology.com Show details

Contact us to learn more about Pyxis Oncology. Contact us to learn more about Pyxis Oncology. following a number of significant pharma deals, to a trade sale to Pfizer in 2007. Amplyx Pharmaceuticals (acquired by Pfizer), Aura Biosciences, Harpoon Therapeutics (NASDAQ IPO) and Imara (NASDAQ IPO). Previously, Mark was a principal at

Category: Contact SupportShow more

Amended Statement of Beneficial Ownership (sc 13d/a)

7 hours ago Ih.advfn.com Show details

Harpoon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 41358P106 (CUSIP Number) Marcus Karia, Group Finance Director. 20 Berkeley Square, Mayfair, London. W1J 6EQ, United Kingdom (Name, Address and Telephone Number of Person Authorized to Receive Notices and …

Category: Contact NumberShow more

ImmuneOnco Biopharma Co., Ltd VentureRadar

Just Now Ventureradar.com Show details

Harpoon Therapeutics USA Private Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, PhD, a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases.

Category: Contact NumberShow more

EX10.14

8 hours ago Sec.gov Show details

1.2 “Covered Product” means any product, the manufacture, use or sale of which would, but for the license under Section 2.1.1, infringe a Valid Claim of the Harpoon Licensed Patents.. 1.3 “Harpoon Assigned Patents” means: (a) the patent applications listed in Exhibit 1.3 attached hereto; (b) all patent applications that claim priority to any patent application referenced in the

Category: Contact NumberShow more

What is Harpoon Therapeutics (NASDAQ:HARP) Valuation

1 hours ago Macroaxis.com Show details

Harpoon Therapeutics retains a regular Real Value of $10.39 per share. The prevalent price of the firm is $6.14. At this time, the firm appears to be undervalued.Our model calculates the value of Harpoon Therapeutics from evaluating the firm fundamentals such as Return On Asset of (19.82) %, return on equity of (154.71) %, and Shares Outstanding of 32.52 M as well as …

Category: Contact NumberShow more

HARP Earnings Date, Forecast and Report (Harpoon Therapeutics)

5 hours ago Marketbeat.com Show details

HARP Earnings Information. Harpoon Therapeutics last released its quarterly earnings results on November 10th, 2021. The reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.01. The business had revenue of $4.48 million for the quarter, compared to the consensus estimate of $6.38 million.

Category: Contact NumberShow more

B Cell Maturation Antigen (BCMA) Targeted Therapy Markets

1 hours ago Galvnews.com Show details

The "Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the

Category: Cell PhoneShow more

Harpoon Therapeutics, Inc. Common Stock (HARP) Stock Price

Just Now Nasdaq.com Show details

About Harpoon Therapeutics, Inc. 131 OYSTER POINT BOULEVARD SUITE 300, SOUTH SAN FRANCISCO, California, 94080, United States +1 650 443 …

Category: Contact NumberShow more

Holger Wesche Net Worth, Biography & Insider Trading History

5 hours ago Insidertrades.com Show details

The corporate mailing address for Dr. Wesche and other Harpoon Therapeutics executives is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Harpoon Therapeutics can also be reached via phone at …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Hms
Holmen
Hyatt